Literature DB >> 27618789

Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III).

Martin Lambert1, Daniel Schöttle1, Mary Sengutta1, Friederike Ruppelt1, Anja Rohenkohl1, Daniel Luedecke1,2, Luise Antonia Nawara1, Britta Galling3, Anne-Lena Falk1, Linus Wittmann1, Vivien Niehaus1, Gizem Sarikaya1, Ute Handwerk4, Wiebke Rothländer4, Liz Rietschel5, Charlotte Gagern6, Benjamin Lange1, Christina Meigel-Schleiff1, Dieter Naber1, Michael Schulte-Markwort2, Helmut Krüger4, Hans-Peter Unger7, Sven Sippel7, Sabine Ott8, Georg Romer9, Anne Daubmann10, Karl Wegscheider10, Christoph U Correll3, Benno G Schimmelmann2,5, Thomas Bock1, Jürgen Gallinat1, Anne Karow1,2.   

Abstract

AIM: The Integrated Care in Early Psychosis (ACCESS III) Study examined the efficacy and cost-effectiveness of a combined intervention consisting of strategies to improve early detection and quality of care (integrated care including therapeutic assertive community treatment) in adolescents and young adults in the early phase of a severe psychotic disorder from 2011 to 2014.
METHODS: This is a prospective, single-centre, 1-year cohort study comparing an intervention condition (early detection plus integrated care, n = 120) to the historical control condition (standard care, SC, n = 105) for adolescents and young adults aged 12-29 years suffering from a severe, early-phase psychotic disorder (i.e. within 2 years of treatment).
RESULTS: Primary outcome is the rate of combined symptomatic (i.e. Positive and Negative Syndrome Scale (PANSS) criteria) and functional (i.e. Global Assessment of Functioning scale (GAF) ≥ 60 points criterion) remission over at least 6 months at study endpoint. Secondary outcome comprises the comparison of the reduction in the duration of untreated psychosis within the 4-year study duration between integrated care and SC, course of psychopathology, functioning, quality of life, satisfaction with care, cost and quality-adjusted life years (QALYs) in comparison to a historical control group.
CONCLUSION: To the authors' knowledge, this is the first study assessing the efficacy and cost-effectiveness of a combined intervention consisting of early detection strategies and strategies to improve quality of care in both adolescents and young adults with early-phase psychosis. The results will be published in 2016.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  bipolar disorder; early detection; early psychosis; integrated care; schizophrenia

Mesh:

Year:  2016        PMID: 27618789     DOI: 10.1111/eip.12361

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  4 in total

1.  Social determinants of health and depression in adults presenting to the emergency department: Implications for family medicine.

Authors:  Lilian Shyman; Roman Sukhorukov; David Barbic; Steve Mathias; Shannon Chau; Adelena Leon; Skye Barbic
Journal:  Can Fam Physician       Date:  2021-12       Impact factor: 3.275

2.  The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders.

Authors:  Nikolai Albert; Marianne Melau; Heidi Jensen; Lene Halling Hastrup; Carsten Hjorthøj; Merete Nordentoft
Journal:  NPJ Schizophr       Date:  2017-09-26

3.  Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment.

Authors:  Daniel Schöttle; Friederike Ruppelt; Benno G Schimmelmann; Anne Karow; Alexandra Bussopulos; Jürgen Gallinat; Klaus Wiedemann; Daniel Luedecke; Anja Christine Rohenkohl; Christian G Huber; Thomas Bock; Martin Lambert
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

4.  "It cannot be boring!": Developing a measure of function for young adults accessing integrated youth services.

Authors:  Skye Barbic; Emily Brooks; Natalia Lassak; Mo Khaleghi; Marco Zenone; Nikki Ow; Adelena Leon; Steve Mathias
Journal:  J Patient Rep Outcomes       Date:  2022-09-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.